Inactive Instrument

Agentix Corp. Other OTC

AGTX

US00848A1034

Agentix Corp. Reports Earnings Results for the First Quarter Ended November 30, 2019

January 16, 2020 at 08:08 pm

Agentix Corp. announced earnings results for the first quarter ended November 30, 2019. For the first quarter, the company announced operating loss was USD 5,032 compared to USD 42,996 a year ago. Net loss was USD 9,556 compared to USD 45,324 a year ago. Basic loss per share from continuing operations was USD 0.42 compared to USD 2.2 a year ago.

Latest news about Agentix Corp.

Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-20	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended June 30, 2023	22/08/23	CI
Agentix Corp. Reports Earnings Results for the Full Year Ended March 31, 2023	14/07/23	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	13/07/23	CI
Agentix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended June 30, 2022	11/08/22	CI
Agentix Corp. Reports Earnings Results for the Seven Months Ended March 31, 2022	18/07/22	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	17/07/22	CI
Agentix Corp. Appoints Salman Hoda as Member of the Board of Directors	14/06/22	CI
Agentix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022	13/04/22	CI
Agentix Corp. Reports Earnings Results for the First Quarter Ended November 30, 2021	13/01/22	CI
Agentix Corp. Auditor Raises 'Going Concern' Doubt	06/10/21	CI
Agentix Corp. completed the acquisition of Applied BioPharma LLC.	30/07/21	CI
Agentix Corp. entered into an Agreement and Plan of Merger to acquire Applied BioPharma LLC.	13/07/21	CI
Agentix Corp. Reports Earnings Results for the Third Quarter Ended May 31, 2021	09/07/21	CI
Agentix Corp. Announces Resignation of Scott Stevens Resigned as A Director	04/06/21	CI
Agentix Corp. Reports Earnings Results for the Second Quarter Ended February 28, 2021	29/03/21	CI
GSL Healthcare, Inc. completed the acquisition of Agentix Corp. in a reverse merger transaction.	31/05/20	CI
GSL Healthcare, Inc. entered into an agreement to acquire Agentix Corp. in a reverse merger transaction for CAD 0.84 million.	28/05/20	CI

Chart Agentix Corp.

Duration

Period

More charts

Company Profile

Agentix Corp. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic agents for the treatment of metabolic diseases like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM). AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease. The Company is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is the regulatory system which governs metabolism. The Companyâs wholly owned subsidiaries include GSL Healthcare, Inc., Agentix Australia Pty Ltd, and Applied Biopharma LLC.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+4.57%	96.72B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.43B
BIOGEN INC.	-13.11%	32.7B
UCB	+81.75%	29.06B
BIOMARIN PHARMACEUTICAL INC.	-15.80%	15.38B
INCYTE CORPORATION	-8.84%	12.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	11.36B
ALTEOGEN INC.	+160.91%	9.9B
SWEDISH ORPHAN BIOVITRUM AB	+3.37%	8.93B

Biopharmaceuticals